INTRODUCTION
A role for 1,25-dihydroxyvitamin D3 (l, in the regulation of thyrotroph function was sus¬ pected following the demonstration of specific binding of [3H] l,25-(OH)2D3 in the nucleus of the thyrotroph in the normal rat pituitary gland (Sar, Stumpf & DeLuca, 1980) . Receptors for the hormone are present in rat pituitary somatomammotrophic (GH) cells (Murdoch & Rosenfeld, 1981; Haussler, Manolagas & Deftos, 1982) . In the GH4C, subclone, treatment of cultures with 1,25-(OH)2D3 led to a selective increase in prolactin production, prolactin secretion and pro¬ lactin mRNA (Wark & Tashjian, 1982 Wark & Gürtler, 1987 (Tornquist & Lamberg-Allardt, 1987a ).
The action of TRH is not fully understood. Following binding of TRH to its membrane receptor there occur increases in intracellular Ca2+ (Albert & Tashjian, 1984 , 1985 Brenner-Gati & Gershen¬ gorn, 1986 ) and cyclic AMP (Dannies, Gautvik & Tashjian, 1976; Brostrom, Brostrom, Brotman & Green, 1983) , and phosphorylation of specific intra¬ cellular proteins (Drust & Martin, 1982 Sobel & Tashjian, 1983) . It is now generally believed that an important early event is the breakdown of phos¬ phatidylinositol 4,5-bisphosphate to inositol 1,4,5-trisphosphate and diacylglycerol (DAG), which act as second messengers leading to increased intracellular Ca2+ and protein kinase C activation respectively (Gershengorn, 1986) . As changes in intracellular Ca2+ have an important role in hormone release, we used several approaches to assess the role of Ca2+ in the enhancement of TSH secretion following pre¬ treatment of cultures with l,25-(OH)2D3. Hormone release following potassium-induced depolarization of the plasma membrane was studied. The effect of the Ca^+ channel agonist BAY 8644 (methyl-1, 4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)-pyridine-5-carboxylate), the antagonist nife¬ dipine, and the Ca2+-selective divalent cation iono¬ phore ionomycin (ll,19,21-tri-hydroxy-4,6,8,12,14, 18,20-heptamethyl-9-oxo-22-(tetrahydro-5-methyl-5-tetrahydro - (Wark & Gurtler, 1987) (Drouin, Lagace & Labrie, 1976) , following one wash using this medium. The Ca2+ concentration of the culture medium was 1 -2 mmol/1 unless otherwise stated.
For experiments requiring a low-Ca2+ experimental medium, CTFBS was mixed with 10% (w/v) Chelex-100 resin (Biorad, Hornsby, Australia) at 4°C for 8 h, centrifuged at 10 000 g for 10 min at 4°C, passed through a 0-2 pm filter and added to Ca2+-free Ham's F12 medium (Flow Laboratories shown). Potassium depolarization induced a concen¬ tration-dependent increase in prolactin secretion (Fig. lb) . However, there was no effect of 1,25-(OH)2D3 on KC1-or TRH-induced prolactin release.
A concentration-dependent increase in prolactin release was caused by BAY 8644 (Fig. 2b) , with BAY 8644 (1 pmol/l)-induced prolactin release being similar to that seen with 60 mmol KC1/1. How¬ ever, the addition of BAY 8644 did not result in TSH release either with or without pretreatment with 10 nmol l,25-(OH)2D3/l (Fig. 2a) ; nor did 1,25-(OH)2D3 alter BAY 8644-induced prolactin release under any of the conditions tested.
Addition of ionomycin resulted in increased prolactin release unaffected by pretreatment with l,25-(OH)2D3 (Fig. 3b) . However, ionomycin had no effect on TSH release, nor did pretreatment with 1,25-(OH)2D3 result in any ionomycin-induced TSH release (Fig. 3a) .
Treatment of the cultures with nifedipine for 30 min before and during KC1 (60 mmol/l)-induced depolari¬ zation resulted in a concentration-dependent inhibition of KCl-induced prolactin and TSH release (Fig.  4) . Nifedipine (10 pmol/1) decreased non-stimulated prolactin secretion by 53% (Fig. 4b) ; non-stimulated secretion refers to secretion by cultures maintained at a KC1 concentration of 3 mmol/1. Nifedipine, at concentrations of 100 nmol/1 or greater, decreased KCl-induced prolactin release to less than the nonstimulated control, and maximal inhibition was obtained with 1 pmol nifedipine/1 (P<001). How¬ ever, nifedipine did not reduce KCl-induced prolactin release to the levels observed in non-stimulated, nife¬ dipine (10pmol/l)-treated cultures. Pretreatment with 10nmol l,25-(OH)2D3/l had no effect on prolactin secretion. Nifedipine had no effect on non-stimulated TSH secretion (Fig. 4a) (Sar, Miller & Stumpf, 1981 Wistar rats (Tornquist & Lamberg-Allardt, 1987a (Hochberg, Borochowitz, Benderli et al. 1985) . The sensitization to extracellular Ca2+ in the thyrotroph is similar to the effect of l,25-(OH)2D3 observed in GH4C, cells (Wark & Tashjian, 1982 (Spedding, 1985) . Unlike TRH, KC1 does not lead to increased breakdown of phosphoinositides (Rebecchi & Gershengorn, 1983) , nor is there phosphorylation of 12-O-tetradecanoylphorbol-13-acetate sensitive protein substrates (Sobel & Tashjian, 1983; Drust & Martin, 1984 (Wark & Gürtler, 1988 Thomas, Towart & Franckowiak, 1983; Kokubun & Reuter, 1984; Enyeart, Aizawa & Hinkle, 1986 (Caron, Beaulieu, Raymond et al. 1978 ; Dannies & Rudnick, 1980) , Ca2+ antagonists (Enyeart, Aizawa & Hinkle, 1985; see Fig. 4b ) and somatostatin (Epelbaum, Enjalbert, Krantic et al. 1987 ) suppress non-stimulated prolactin secretion. In contrast, the thyrotroph is removed from its major stimulatory factor, TRH, and it may be speculated that the thyrotroph would have a low frequency of Ca2+ channel opening, consistent with the inability of nifedipine (see Fig. 4a ) and somatostatin to decrease basal TSH secretion (Epelbaum et al. 1987 (Spedding, 1985 (Albert & Tashjian, 1984 (Pressman & Fahim, 1982;  Knight & Baker, 1983; Koenig, Senator & Larsen, 1984) , but also generated DAG (Kolesnick & Gershengorn, 1984) , damaged plasma membranes (Knight & Baker, 1983) and caused intracellular disruption and cell death (Pressman & Fahim, 1982 (Tornquist & LambergAllardt, 19876) and TRH-induced TSH release is increased in normal human subjects given 1,25-(OH)2D3 (Zofkova & Bednar, 1988) . Also, a number of interactions between 1,25-(OH)2D3 and the thyroid axis exist. Tri-iodothyronine regulates renal lahydroxylase (Kano & Jones, 1984) ; hypothyroid patients have higher circulating l,25-(OH)2D3 levels than normal patients (Bouillon, Muls & De Moor, 1980) and there are histological changes in the thyroid gland in patients with rickets (Glanzmann, 1934) 
